
Opinion|Videos|June 5, 2025
First-Line Treatment Approaches for EGFR-mutated Metastatic NSCLC: Updates from MARIPOSA High-Risk Analyses
Author(s)Rachel E. Sanborn, MD
An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and FLAURA2, and shares their impression of icPFS and DoR from MARIPOSA, along with how to determine which patients are best suited for either combination treatment option.
Advertisement
Episodes in this series

- Please discuss a treatment approach for the patient case above.
- How do factors like brain metastases influence your 1L treatment choice?
- How do you determine which patients are best suited for either combination treatment option?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















